The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer Men with prostate cancer stage cT1c-T2bN0M0, ...

Long-term results from a phase 3 study showed that adding a focal boost to standard external beam radiotherapy (EBRT) improved 10-year biochemical disease-free survival (DFS) and reduced biochemical ...

Over a median follow-up period of more than five years, patients were asked to complete repeated questionnaires logging bowel, urinary and sexual function after receiving one of the two radiation ...

Treatment with five-fraction SBRT for prostate cancer may be more convenient than receiving traditional radiation therapy techniques, an expert said. For patients with low- to intermediate-risk ...

If you or a loved one has been diagnosed with prostate cancer, you’re not alone—and you don’t have to wait long to take the next step. Whether you’re newly diagnosed, moving from active surveillance ...

People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy - proton beam therapy or intensity modulated radiation therapy (IMRT) - ...

If the US FDA approves it, aglatimagene immunotherapy may become the first new therapy for men with localized prostate cancer in the past 2 decades.

Prostatectomy and radiation therapy show no survival difference for low-risk prostate cancer, but higher-risk cases require careful treatment consideration. The ProtecT trial supports active ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...

CHICAGO -- An investigational viral immunotherapy (CAN-2409; aglatimagene besadenovec) combined with a prodrug improved disease-free survival (DFS) when added to standard curative-intent radiotherapy ...